ProCE Banner Activity

Small Cell Lung Cancer: Applying the Latest Developments in Community Practice

Slideset Download
Download this slideset from a live workshop series to learn how the experts are leveraging immunotherapy and chemotherapy to manage newly diagnosed and relapsed extensive-stage SCLC, from treatment selection to dosing considerations to managing adverse events.

Released: August 18, 2022

Expiration: August 17, 2023

Share

Faculty

Christine L. Hann

Christine L. Hann, MD, PhD

Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Mark A. Socinski

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

G1 Therapeutics Inc

Ipsen Biopharmaceuticals Inc

Program Director Disclosure

Program Director

Christine L. Hann, MD, PhD

Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Christine L. Hann, MD, PhD, has disclosed that she has received consultant/advisor/speaker fees from Amgen, AstraZeneca, and Janssen and funds for research support from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, and Genentech.

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Mark A. Socinski, MD, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, BeiGene, G1 Therapeutics, Genentech, Guardant, Janssen, Jazz, Lilly, Regeneron, Takeda, and Sanofi and funds for research support from AstraZeneca, BeiGene, Cullinan, Daiichi-Sankyo, Genentech, Novartis, Spectrum, and Takeda.